S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:CFRX

ContraFect - CFRX Stock Forecast, Price & News

$0.31
-0.01 (-3.15%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.30
$0.32
50-Day Range
$0.28
$4.45
52-Week Range
$0.28
$4.54
Volume
2.20 million shs
Average Volume
779,588 shs
Market Capitalization
$12.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

ContraFect MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
1,337.7% Upside
$4.50 Price Target
Short Interest
Healthy
2.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of ContraFect in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.29) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

358th out of 1,119 stocks

Pharmaceutical Preparations Industry

165th out of 549 stocks

CFRX stock logo

About ContraFect (NASDAQ:CFRX) Stock

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. WBB Securities upgraded ContraFect to a "strong-buy" rating and set a $7.00 target price for the company in a report on Wednesday, June 8th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $1.00 target price (down from $15.00) on shares of ContraFect in a report on Thursday, July 14th. SVB Leerink lowered ContraFect from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $9.00 to $1.00 in a report on Thursday, July 14th. Maxim Group lowered ContraFect from a "buy" rating to a "hold" rating in a report on Thursday, July 14th. Finally, StockNews.com began coverage on ContraFect in a report on Tuesday. They issued a "sell" rating for the company. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $4.50.

ContraFect Price Performance

ContraFect stock opened at $0.32 on Thursday. ContraFect has a 1-year low of $0.28 and a 1-year high of $4.54. The stock has a market cap of $12.42 million, a PE ratio of -0.26 and a beta of 0.05. The stock's fifty day moving average is $1.76 and its two-hundred day moving average is $2.87.

ContraFect (NASDAQ:CFRX - Get Rating) last posted its earnings results on Monday, May 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.18). On average, research analysts expect that ContraFect will post -1.29 earnings per share for the current fiscal year.

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Stock News Headlines

ContraFect: Q2 Earnings Insights - Benzinga
ContraFect (NASDAQ:CFRX) Coverage Initiated at StockNews.com
StockNews.com Begins Coverage on ContraFect (NASDAQ:CFRX)
DSMB Recommendation - Benzinga
See More Headlines
Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Company Calendar

Last Earnings
11/15/2021
Today
8/18/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFRX
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,362.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-20,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.33 per share

Miscellaneous

Free Float
37,917,000
Market Cap
$12.10 million
Optionable
Not Optionable
Beta
0.05

Key Executives

  • Dr. Roger James Pomerantz F.A.C.P. (Age 65)
    FACP, M.D., Chairman, CEO & Pres
    Comp: $1.27M
  • Mr. Michael Messinger CPA (Age 47)
    CPA, Chief Financial Officer
    Comp: $620.25k
  • Dr. Cara M. Cassino M.D. (Age 60)
    Chief Medical Officer and Exec. VP of R&D
    Comp: $823.72k
  • Ms. Natalie Bogdanos J.D. (Age 53)
    Gen. Counsel, Corp. Sec. & Data Protection Officer
  • Mr. Matthew Salamone P.H.R.
    SPHR, VP of HR
  • Dr. Gary Woodnutt (Age 65)
    Sr. VP of Translational Sciences & Preclinical Devel.
  • Ms. Kristina Haeckl Rac
    Sr. VP of Regulatory Affairs & Quality Systems













CFRX Stock - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings
or view top-rated stocks.

What is ContraFect's stock price forecast for 2022?

5 Wall Street analysts have issued twelve-month target prices for ContraFect's shares. Their CFRX share price forecasts range from $1.00 to $9.00. On average, they predict the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 1,325.0% from the stock's current price.
View analysts price targets for CFRX
or view top-rated stocks among Wall Street analysts.

How have CFRX shares performed in 2022?

ContraFect's stock was trading at $2.63 at the beginning of the year. Since then, CFRX shares have decreased by 88.0% and is now trading at $0.3158.
View the best growth stocks for 2022 here
.

When is ContraFect's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our CFRX earnings forecast
.

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.15.

When did ContraFect's stock split?

ContraFect shares reverse split on Tuesday, February 4th 2020. The 1-10 reverse split was announced on Tuesday, February 4th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by many different retail and institutional investors. Top institutional shareholders include Silverarc Capital Management LLC (0.00%), White Pine Capital LLC (1.00%), Prospera Financial Services Inc (0.91%), DLD Asset Management LP (0.00%), MAI Capital Management (0.65%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Cary Sucoff and Michael Messinger.
View institutional ownership trends
.

How do I buy shares of ContraFect?

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $0.32.

How much money does ContraFect make?

ContraFect (NASDAQ:CFRX) has a market capitalization of $12.42 million. The biotechnology company earns $-20,280,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.

This page (NASDAQ:CFRX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.